Valbenazine in the treatment of tardive dyskinesia

Neurodegener Dis Manag. 2019 Apr;9(2):73-81. doi: 10.2217/nmt-2019-0001. Epub 2019 Feb 6.

Abstract

Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 2017, valbenazine became the first US FDA-approved medication indicated for the treatment of TD. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. The FDA considered valbenazine a breakthrough therapy in 2014 given its underlying mechanism and its importance in addressing an unmet need, as there were no available FDA-approved medications indicated for TD. The advantages of valbenazine include once-daily dosing and a rapid onset of effect within 2 weeks of treatment initiation.

Keywords: VMAT2 inhibitor; tardive dyskinesia; valbenazine.

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology*
  • Dopamine Antagonists / adverse effects*
  • Humans
  • Tardive Dyskinesia / chemically induced
  • Tardive Dyskinesia / drug therapy*
  • Tetrabenazine / analogs & derivatives*
  • Tetrabenazine / pharmacology
  • Valine / analogs & derivatives*
  • Valine / pharmacology
  • Vesicular Monoamine Transport Proteins / antagonists & inhibitors*

Substances

  • Adrenergic Uptake Inhibitors
  • Dopamine Antagonists
  • Vesicular Monoamine Transport Proteins
  • valbenazine
  • Valine
  • Tetrabenazine